You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial
|
|---|---|
| Published in |
Lancet Oncology, December 2015
|
| DOI | 10.1016/s1470-2045(15)00447-7 |
| Pubmed ID | |
| Authors |
Mathias Rummel, Ulrich Kaiser, Christina Balser, Martina Stauch, Wolfram Brugger, Manfred Welslau, Norbert Niederle, Christoph Losem, Hans-Peter Boeck, Eckhart Weidmann, Ulrich von Gruenhagen, Lothar Mueller, Michael Sandherr, Lars Hahn, Julia Vereshchagina, Frank Kauff, Wolfgang Blau, Axel Hinke, Juergen Barth, Study group indolent Lymphomas |
X Demographics
The data shown below were collected from the profiles of 16 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 3 | 19% |
| United States | 3 | 19% |
| Spain | 1 | 6% |
| Unknown | 9 | 56% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 13 | 81% |
| Practitioners (doctors, other healthcare professionals) | 3 | 19% |
Mendeley readers
The data shown below were compiled from readership statistics for 200 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Germany | 1 | <1% |
| Unknown | 198 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 40 | 20% |
| Other | 24 | 12% |
| Student > Bachelor | 14 | 7% |
| Student > Ph. D. Student | 12 | 6% |
| Student > Postgraduate | 12 | 6% |
| Other | 50 | 25% |
| Unknown | 48 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 97 | 49% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 6% |
| Biochemistry, Genetics and Molecular Biology | 9 | 5% |
| Agricultural and Biological Sciences | 8 | 4% |
| Unspecified | 5 | 3% |
| Other | 13 | 7% |
| Unknown | 57 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 31. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 February 2022.
All research outputs
#1,303,678
of 25,837,817 outputs
Outputs from Lancet Oncology
#1,487
of 6,943 outputs
Outputs of similar age
#21,426
of 397,922 outputs
Outputs of similar age from Lancet Oncology
#23
of 162 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,943 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.3. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 397,922 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 162 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.